What the Word Peptide Is Doing in the Query
Twenty nine residues, one molecular weight and one PubChem entry. Everything else on a listing is downstream of whether the vial matches those.
People who buy sermorelin peptide rather than just sermorelin are usually asking a sharper question: what molecule is in the vial. It has an exact answer, and confirming it against a certificate takes about two minutes.
Where the order actually gets placed
Ascension Peptides, Sermorelin
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The published certificate for lot 38-01260229 assays this vial at 11.31 mg against a 10 mg label, and reports purity and quantity only, with no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Batch certificate published for this lot
- Shipping free over $250
- Same-day dispatch before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 6, 2026.
Buy sermorelin peptide: the identity you are paying for
Sermorelin is a synthetic peptide of twenty nine amino acids, equal to the active N-terminal fragment of human growth hormone-releasing hormone. The conventional shorthand is GHRH(1-29) amide, and the amide at the C-terminus is part of the definition rather than a detail.
| Property | Value |
|---|---|
| Sequence | YADAIFTNSYRKVLGQLSARKLLQDIMSR |
| Residues | 29, with a C-terminal amide |
| Molecular formula | C149H246N44O42S |
| Molecular weight | 3357.9 g/mol |
| PubChem CID | 16132413 |
| Receptor | The GHRH receptor on the anterior pituitary |
| Class | Secretagogue, not growth hormone |
Those five identifiers are checkable in a browser. PubChem CID 16132413 returns the title Sermorelin with formula C149H246N44O42S and a molecular weight of 3357.9, and any vendor description that disagrees with those is either describing a different compound or has copied its page carelessly. Neither is a good sign.
How a certificate proves identity, and how it fails to
Most certificates in this market lead with a purity percentage, and purity is not identity. Purity says that whatever is present is overwhelmingly one substance. It does not say which substance.
Identity is established by a method that looks at the molecule itself: a mass consistent with 3357.9 g/mol, or a printed sequence that can be read and matched. On lot 38-01260229 there is a sequence, and it converts to YADAIFTNSYRKVLGQLSARKLLQDIMSR, twenty nine residues with a C-terminal amide. That is canonical GHRH(1-29), which means the vial holds the compound the label names.
The analysis behind it was run by MZ Biolabs at 2102 N Country Club Rd, Tucson, Arizona, on 7 February 2026, signed on the thirteenth by Ken Pendarvis, using HPLC-UV-MS with four peaks detected, and it reported 99.79 percent purity alongside a measured quantity of 11.31 mg against a 10 mg label.
A certificate fails the identity test in three recognisable ways. It reports purity with no mass and no sequence, so nothing is confirmed. It carries no lot number, so whatever it confirms belongs to a different vial. Or it is undated and unsigned, so no organisation has attached its name to the claim. Our vetting sequence puts those checks in the order that eliminates the most sellers fastest.
Secretagogue, not growth hormone
This is the distinction the word peptide in the search query is usually circling, and it is worth stating flatly.
Sermorelin binds the GHRH receptor on the anterior pituitary and prompts the pituitary to release the body's own growth hormone. It does not supply growth hormone. Growth hormone is a different, far larger molecule administered directly, and the two are not substitutes for one another in any sense that matters to a buyer.
That difference is also visible in the regulatory record. Sermorelin was approved as Geref under NDA 019863 for pituitary diagnostics and NDA 020443 for therapeutic use, approved on 26 September 1997, both from EMD Serono and both now discontinued, with FDA's record carrying the determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. Its approved indications were paediatric growth hormone deficiency and pituitary diagnostics, and a diagnostic application makes sense for a compound that provokes the pituitary and lets you observe what it does. That is what a secretagogue is for.
Four compounds sold as one category
The shelf beside sermorelin is crowded, and the compounds on it are routinely presented as versions of the same idea. They are four different purchases with four different regulatory positions.
| Compound | What it is | Where it sits with FDA |
|---|---|---|
| Sermorelin | GHRH(1-29) amide, acts at the GHRH receptor | Was approved as Geref, now discontinued and not withdrawn for safety. Absent from the Category 2 list |
| Tesamorelin | A stabilised GHRH analog | Currently approved, marketed as Egrifta |
| Ipamorelin | Acts at the ghrelin and growth hormone secretagogue receptor | Ipamorelin acetate is on FDA's Category 2 list under 503B |
| Ibutamoren, MK-677 | Also acts at the growth hormone secretagogue receptor, orally active | Ibutamoren mesylate is on Category 2 under both 503A and 503B, the strongest listing in this group |
Two rows of that table are the whole argument for treating these as separate decisions. Sermorelin is absent from FDA's Category 2 list of bulk substances identified as presenting significant safety risks, in any section, active or withdrawn. Ibutamoren mesylate appears on it twice. GHRP-2 and GHRP-6 appear on it as well, and kisspeptin-10 appears under 503A.
That absence is not an oversight, and it is not a gap waiting to be filled. Sermorelin acetate was a component of an FDA-approved drug product, which is the basis on which a 503A compounding pharmacy may compound with a bulk substance, so it never needed to be nominated to the list at all. The consequence is a real prescription route, covered on our sermorelin prescription page.
Why the substitution happens
Vendors and clinics group these compounds because they sit near each other in the same conversation about growth hormone, and because a buyer who cannot distinguish them is a buyer who can be sold whichever one is in stock.
The practical risk is not usually fraud. It is that a listing headed sermorelin links to a certificate for a related compound, or that a blend vial contains sermorelin plus something the certificate does not itemise. Both are resolved by the same two minute check: read the identity data, match it against 3357.9 g/mol and the twenty nine residue sequence, and confirm the lot number ties the document to your vial.
The grouping also does real damage to how people compare prices. A per-milligram figure quoted across this category treats four molecules with four different masses and four different regulatory positions as though they were grades of one product, and the cheapest number in such a comparison usually belongs to whichever compound is easiest to make rather than to the one the reader came for. Comparing cost only makes sense within a single molecule, which is why our price arithmetic stays on one listing rather than ranging across the shelf.
Reading the identity data without a chemistry background
None of these checks require you to interpret a chromatogram, which is the assumption that stops most people from running them.
Start with the sequence, if one is printed. It is a string of single-letter amino acid codes, and the only thing you have to do is count the letters and compare the string. Twenty nine letters, beginning YADAIF and ending IMSR. A shorter or longer string is a different molecule, and a string that matches is the strongest single piece of evidence a certificate can carry.
If there is no sequence but there is a mass, compare it against 3357.9. Certificates report this in different ways and the figure you want is the one describing the intact molecule. A value in the low three thousands that rounds to 3357 or 3358 is consistent. A value that is not in that neighbourhood at all is describing something else, and no amount of purity fixes that.
If there is neither, you have a purity certificate rather than an identity certificate, and you are relying entirely on the label. That is the situation most of this market is actually in, and it is worth recognising it for what it is rather than assuming the missing test simply went unmentioned.
The number of detected peaks is the last thing worth glancing at. On lot 38-01260229 the method was HPLC-UV-MS and four peaks were detected, alongside a 99.79 percent purity result. Peaks beyond the main one are normal in a real analysis; what matters is that the report states them rather than presenting a single idealised line.
What identity does not settle
Confirming the molecule is necessary and it is not sufficient, and this is where a page like this usually stops early.
It does not settle testing scope. The certificate for lot 38-01260229 reports purity and quantity and carries no endotoxin test and no sterility test. FDA's stated concern for the peptides it placed in Category 2 is the "risk for immunogenicity ... due to the potential for aggregation and peptide-related impurities", which those two absent assays speak to and a purity figure does not.
It does not settle the evidence either. PubMed returns 332 papers mentioning sermorelin, three with it in the title, and zero for sermorelin and anti-aging. ClinicalTrials.gov registers no studies naming sermorelin at all, so any trial identifier cited for this compound was invented, most likely by conflating GHRH or tesamorelin studies with sermorelin ones.
The three title papers are a 2006 review in Clinical Interventions in Aging on adult-onset growth hormone insufficiency, a 1999 BioDrugs review on diagnosis and treatment in children with idiopathic growth hormone deficiency, and a 2021 paper in Annals of Translational Medicine on recurrent glioma. Knowing exactly which molecule you have bought is worth doing. It is not the same as knowing what it has been shown to do.